Immunotherapy for cancer in the central nervous system: Current and future directions.
Immunotherapy for cancer in the central nervous system: Current and future directions.
复制标题
DOI：
10.1080/2162402x.2015.1082027
复制
发表时间：
2016-02
期刊：
影响因子：
7.2
通讯作者：
Wainwright DA
中科院分区：
文献类型：
--
作者：
Binder DC;Davis AA;Wainwright DA
多形性胶质母细胞瘤（GBM）是成人中最常见的原发性脑肿瘤，仍然无法治愈。尽管针对GBM的免疫接种已经证明具有免疫刺激活性和一些有希望的生存益处，但肿瘤复发是常见的，突出了对额外和/或组合方法的需要。最近，针对免疫检查点的抗体被证明可以对晚期黑色素瘤和其他恶性肿瘤产生令人印象深刻的临床反应，此外还显示出增强疫苗接种和放疗（RT）的潜力。在这里，我们总结了中枢神经系统（CNS）免疫抑制的现有知识，评估过去和目前的免疫试验，并讨论有前途的未来免疫治疗的方向，以治疗中枢神经系统定位的恶性肿瘤。
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and still remains incurable. Although immunotherapeutic vaccination against GBM has demonstrated immune-stimulating activity with some promising survival benefits, tumor relapse is common, highlighting the need for additional and/or combinatorial approaches. Recently, antibodies targeting immune checkpoints were demonstrated to generate impressive clinical responses against advanced melanoma and other malignancies, in addition to showing potential for enhancing vaccination and radiotherapy (RT). Here, we summarize the current knowledge of central nervous system (CNS) immunosuppression, evaluate past and current immunotherapeutic trials and discuss promising future immunotherapeutic directions to treat CNS-localized malignancies.